Lyell Immunopharma Inc (LYEL) Actualités

Form ARS - Annual Report to Security Holders

Form DEF 14A - Other definitive proxy statements

Lyell Immunopharma Receives Regenerative Medicine Advanced Therapy (RMAT) Designation for LYL314 for the Treatment of Relapsed and/or Refractory Large B-Cell Lymphoma

RMAT designation was granted based on promising clinical data from the ongoing Phase 1/2 trial of LYL314 in...

Form PRE 14A - Other preliminary proxy statements

Form 8-K - Current report

Form 4 - Statement of changes in beneficial ownership of securities

Form S-8 - Securities to be offered to employees in employee benefit plans

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Form 8-K - Current report

Lyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarter and Full Year 2024

Acquired ImmPACT Bio and strengthened clinical pipeline with the addition of IMPT-314, a next-generation...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Lyell Immunopharma Announces Participation in Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a...

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]